Curewize aims to increase the rate of survival and improve the overall health outcome of cancer patients. The Company's lead product is ProALLTM a groundbreaking lab test for deciding on the treatment intensity of acute lymphoblastic leukemia (ALL) patients. ProALL is planned to be available during Q4 2017 after completing the assay's third clinical validation. ProALL will gain fast market entry via CLIA labs in USA and CE in Europe and India. ProALL has the advantage of a receptive market with validated patient need.
Curewize is forming partnerships for the development of miRNA lab tests for diagnosis and personalized medicine of cancer patients. Curewize pipeline includes the ProALL blood test for frequent and long-term monitoring of patients and a companion diagnostic test for precision treatment of solid cancers.
Curewize gains value from its own proprietary platform technology, large biomarker pipeline for several cancers and management experienced in successfully taking a lab test from concept to sales.
Curewize systematic approach to clinically developing and commercializing proven biomarkers is associated with much less risk than other biotechnology companies that use funds for discovering novel technologies.